Fate Therapeutics, Inc.
Fate Therapeutics, Inc.
IND Enabling
Phase I
Phase II
Phase III
Relapsed or Refractory B-cell Lymphoma and Chronic Lymphocytic Leukemia, (NCT04245722)
Sponsors:
Fate Therapeutics
Sponsors:
Fate Therapeutics
IND Enabling
Phase I
Phase II
Phase III
IND Enabling
Phase I
Phase II
Phase III
IND Enabling
Phase I
Phase II
Phase III
IND Enabling
Phase I
Phase II
Phase III
IND Enabling
Phase I
Phase II
Phase III
IND Enabling
Phase I
Phase II
Phase III
IND Enabling
Phase I
Phase II
Phase III